Abiraterone

• A Study to Test Inavolisib Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Recruiting
  2025-521327-67-00 Phase II 4 countries F. Hoffmann-La Roche AG
• A clinical trial to learn about the effects of AMO959 given with AAA617 and an androgen receptor pathway inhibitor (ARPI) in adults with PSM… Recruiting
  2025-521859-23-00 Phase I/II 4 countries Novartis Pharma AG
• A clinical trial to learn about the effects of DZR123 and JSB462 given together in men with advanced prostate cancer that has stopped respon… Recruiting
  2025-521880-10-00 Phase I/II 6 countries Novartis Pharma AG
• TulmiSTAR-02: Phase I/II open-label study of tulmimetostat in combination with darolutamide vs. darolutamide, and tulmimetostat with abirat… Recruiting
  2025-521873-15-00 Phase I/II 5 countries Novartis Pharma AG
• An open-label study of JSB462 (luxdegalutamide) in combination with abiraterone in adult male patients with metastatic hormone-sensitive pro… Recruiting
  2024-520156-22-00 Phase II 7 countries Novartis Pharma AG
• A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting
  2024-516036-94-00 Phase I/II 7 countries Merck Sharp & Dohme LLC
• Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting
  2025-521051-23-00 Phase II 1 country Universitaet Muenster
• EORTC-2238-GUCG: Improving impact of anti-androgen treatments on patient's daily life and their cancer Recruiting
  2023-506817-23-01 Phase III 10 countries European Organisation For Research And Treatment Of Cancer
• A first-in-human study of PARP1 selective inhibitor, IMP1734, in patients with advanced solid tumors. Recruiting
  2023-509230-19-00 Phase I (FiH) 3 countries Eikon Therapeutics Inc.
• A Rollover Study for Patients Previously Enrolled in a Genentech and/or F.Hoffman-La Roche Sponsored Study Recruiting
  2023-504263-16-00 Phase III 4 countries F. Hoffmann-La Roche AG
• RAndomized, open label, multicenter study of Docetaxel versus an Androgen Receptor-targeted agent (abiraterone orenzalutamide) as first-line… Recruiting
  2024-518623-30-00 Phase IV 1 country Fondazione Policlinico Universitario Agostino Gemelli IRCCS
• ProBio: An outcome-adaptive and randomised multi-arm biomarker driven study in patients with metastatic prostate cancer Recruiting
  2023-506857-40-00 Phase III 5 countries Karolinska Institutet
• Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365) Recruiting
  2023-506987-15-00 Phase I/II 11 countries Merck Sharp & Dohme LLC
• A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Ended
  2024-517422-25-00 Phase III 12 countries Celgene Corp.
• SatisfACtion: A Phase I/II, open-label, multi-center study of [225Ac]Ac-PSMA-R2 in men with metastatic hormone sensitive prostate cancer (mH… Ended
  2023-507672-52-00 Phase I (FiH) 1 country Novartis Pharma AG
• Lutetium after second-line hormonal treatment [PBP-301] [SPLASH] Ended
  2024-515604-39-00 Phase III 3 countries Point Biopharma Inc.
• An Open-label study comparing 177Lu-PSMA-617 plus Standard of Care vs. Standard of Care in the Treatment of mHSPC Ended
  2023-507970-42-00 Phase III 10 countries Novartis Pharma AG
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-506365-64-00 Phase III 13 countries Janssen - Cilag International
• A Phase 3 Study of Niraparib in Combination with Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment … Ended
  2023-503254-12-00 Phase III 10 countries Janssen - Cilag International
• Study on Olaparib Plus Abiraterone as First-line Therapy in Men with Metastatic Castration-resistant Prostate Cancer Ended
  2024-511144-86-00 Phase III 6 countries AstraZeneca AB
• A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study Ended
  2023-510298-33-00 Phase II 15 countries Astellas Pharma Global Development Inc.

Showing 1–21 of 21 trials